What is it about?
This paper reports findings from a double-masked randomised controlled trial that investigated the effects of oral long-chain omega-3 fatty acid supplementation on peripheral nerve health in individuals with type 1 diabetes, over six months. Based on findings from our recent systematic review (Zhang et al., Nutr Rev, 2020), this is, to our knowledge, the first double-masked RCT to investigate this clinical question.
Featured Image
Photo by Michele Blackwell on Unsplash
Why is it important?
Our major finding is that, relative to placebo, six months of oral long-chain omega-3 fatty acid supplementation promotes neuroregeneration in corneal sensory nerve fibres. These data provide the first robust evidence for oral omega-3 fatty acid supplementation as a disease-modifying intervention that improves small nerve fibre health in individuals with diabetes.
Read the Original
This page is a summary of: Investigating the Neuroprotective Effect of Oral Omega-3 Fatty Acid Supplementation in Type 1 Diabetes (nPROOFS1): A Randomized Placebo-Controlled Trial, Diabetes, May 2021, American Diabetes Association,
DOI: 10.2337/db21-0136.
You can read the full text:
Contributors
The following have contributed to this page
